Pharma

Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Receives Marketing Authorization in Australia

Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has been approved in Australia for treating early-stage Alzheimer’s disease in patients with confirmed amyloid pathology.

Breakthrough "Armoured" CAR T-Cell Therapy Shows Promising Results in Tough-to-Treat Lymphomas

In a phase 1 study, 81% of patients responded to IL18-boosted therapy, with over half achieving complete remission.

Women’s Health Therapeutics Market Enters Transformative Growth Phase

BCC Research’s findings underscore a decisive moment for women’s health therapeutics, a sector finally gaining the investment, innovation, and strategic focus it should.

UK-US Trade Deal: What's in it for Pharma?

Despite the UK securing an initial trade agreement with the US, the pharmaceutical sector remains uncertain, as the deal notably omits specific provisions for medicines, leaving the industry awaiting clearer terms regarding potential tariffs and preferential treatment.

VYNE Therapeutics Faces Clinical Hold on VYN202 Program Following Toxicity Findings

VYNE Therapeutics has paused its Phase 1b trial of VYN202 for psoriasis after the FDA imposed a clinical hold due to testicular toxicity observed in non-clinical studies.

Ascletis Enters the Obesity Drug Spotlight with Bold Play on Oral GLP-1 Candidate

Ascletis advances oral GLP-1 drug ASC30 after Phase 1b shows strong weight loss and safety, shifting focus to obesity with a slower dose-escalation strategy.